Supernus Pharmaceuticals | SUPN - Ebitda


Supernus Pharmaceuticals reported $41.9M in EBITDA for its fiscal quarter ending in September of 2025.





Ebitda Change Date
Abbott USD 3.09B 44M Sep/2025
ANI Pharmaceuticals USD 59.6M 5.52M Sep/2025
Aurora Cannabis CAD 15.37M 26.8M Sep/2025
Bristol-Myers Squibb USD 4.24B 967M Sep/2025
Canopy Growth CAD 16.62M 38.45M Sep/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Eisai JPY 23.48B 14.68B Sep/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Novo Nordisk DKK 31.44B 6.84B Sep/2025
Pacira USD 49.36M 4.96M Sep/2025
Perrigo USD 258.8M 37.3M Sep/2025
Pfizer USD 6.08B 351M Sep/2025
Supernus Pharmaceuticals USD 41.9M 432K Sep/2025
United Therapeutics USD 436.8M 34.2M Jun/2025
Xeris Pharmaceuticals USD 17.42M 8.83M Sep/2025